HomeSGX-LISTED COMPANIESiFAST Corp: Stellar 1H2025 Profit & Growth Surge

iFAST Corp: Stellar 1H2025 Profit & Growth Surge

Published on

spot_img

iFAST Corp reported robust financial results for 2Q2025 and 1H2025, with profitability seeing a significant rise. This performance was primarily driven by the growth in its Hong Kong ePension business, the successful turnaround of iFAST Global Bank, and the continued expansion of the Group’s core wealth management platform business. The Group achieved record highs in assets under administration and net inflows, setting expectations for further healthy growth in the second half of 2025.

• Witness a key business unit’s notable turnaround from previous losses
• Discover new record highs achieved in client assets and incoming investments
• Learn about strong prospects for future growth and increasing shareholder returns

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...